A phase 2 study of berzosertib (M6620) in combination with carboplatin compared with docetaxel in combination with carboplatin in metastatic castration-resistant prostate cancer.
Year: 2021
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Atish Dipankar Choudhury, Wanling Xie, Edmund Folefac, Daniel Lee, Mamta Parikh, David Johnson Einstein, Elizabeth R Kessler, Tina M. Mayer, Rana R. McKay, Amanda Fredericks Pace, Bose Kochupurakkal, Kent William Mouw, Eliezer Mendel Van Allen, Charles Kunos, Alan D. D'Andrea, Mary-Ellen Taplin, Geoffrey Shapiro
Institutions: Dana-Farber Cancer Institute, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, National Cancer Institute, UC Davis Comprehensive Cancer Center, Beth Israel Deaconess Medical Center, University of Colorado Anschutz, Rutgers Cancer Institute, Moores Cancer Center, Summa Health System
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: National Institutes of Health
OpenAlex ID: W4206537005